CA
NZ
UK
AU
IND
US
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on lipid-signaling pathways, has filed a provisional patent application covering the use of ART27.13 for obesity treatment. The filing covers the compound both as a standalone therapy and in combination with GLP-1 receptor agonists such …
Armata Pharmaceuticals, Inc. (NYSE American:ARMP), a late clinical-stage biotechnology company focused on bacteriophage therapeutics, has received an additional 3.7 million dollars in non-dilutive funding from the U.S. Department of War to support Phase 3 development activities for its lead candidate, AP-SA02. The funding was …
Roivant (NASDAQ:ROIV) announced topline results from Period 1 of a proof-of-concept trial evaluating IMVT-1402, known as imeroprubart, for the treatment of cutaneous lupus erythematosus, conducted by its majority-ownedSubsidiaryImmunovant. The randomized, double-blind, placebo-controlled study enrolled 57 patients and assessed percent change from baseline in the …
For shareholders, the approval matters in three ways. It adds a high-priced orphan medicine with strong efficacy data. It puts Regeneron in direct competition with Ipsen's Sohonos, the first FOP therapy, which has sold poorly. It also validates an antibody program that had once …
In the Phase 2b AMPLIFIED study, patients with modest levels of protein in their urine saw urine albumin-to-creatinine ratio, or UACR, fall 42.7% after 13 weeks of treatment. A second cohort of patients who also had type 2 diabetes showed a smaller 17.3% reduction. …
The shares rose 3.4% on September 2. The gain appeared tied mainly to continued investor reaction to the August 30 ESC update, and no major new regulatory filing coincided with the move.
Several things drove the rebound. SomeWall Streetanalysts argued that olpasiran has a different profile from the program that failed, which eased fears that the whole Lp(a) drug class had been undermined. Amgen also delivered two pieces of good news in the same period. On …
The new revenue range is $5.18 billion to $5.25 billion, which the company said implies growth of about 11% to 13%. The previous range was $5.16 billion to $5.25 billion, so the upgrade raised the low end and the midpoint rather than the ceiling. …
At the new rate, the annual payout is $0.16 per share. With roughly 453 million shares outstanding, that is a modest cash outlay compared with the approximately $1.6 billion of freeCash Flowthe company has guided for 2026. The increase therefore reads less as a …
Bixlenvo followed two other U.S. decisions this year. The FDA grantedAccelerated Approvalto Hepcludex for chronic hepatitisDeltavirus infection on May 22, and on June 24 Trodelvy received approvals in first-line metastatic triple-negative breast cancer. Gilead shares were up more than 21% year to date as …
Please wait processing your request...